OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥230,406 | ¥201,485 | ¥186,750 | ¥338,000 |
| % Growth | 14.4% | 7.9% | -44.7% | – |
| Cost of Goods Sold | ¥197,814 | ¥205,019 | ¥175,684 | ¥297,581 |
| Gross Profit | ¥32,592 | -¥3,534 | ¥11,066 | ¥40,419 |
| % Margin | 14.1% | -1.8% | 5.9% | 12% |
| R&D Expenses | ¥104,322 | ¥182,657 | ¥128,860 | ¥99,877 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥100,283 | ¥117,734 | -¥17,933 | ¥108,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | -¥34,000 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥17,933 | -¥99,877 |
| Operating Expenses | ¥204,605 | ¥300,391 | ¥128,860 | ¥108,000 |
| Operating Income | -¥172,013 | -¥303,925 | -¥117,794 | -¥167,000 |
| % Margin | -74.7% | -150.8% | -63.1% | -49.4% |
| Other Income/Exp. Net | -¥68,213 | -¥9,900 | ¥20,281 | -¥5,000 |
| Pre-Tax Income | -¥240,226 | -¥313,825 | -¥97,513 | -¥172,000 |
| Tax Expense | ¥540 | ¥540 | ¥540 | ¥80 |
| Net Income | -¥240,766 | -¥314,365 | -¥98,053 | -¥172,000 |
| % Margin | -104.5% | -156% | -52.5% | -50.9% |
| EPS | -0.76 | -1.13 | -0.36 | -0.63 |
| % Growth | 32.7% | -213.9% | 42.9% | – |
| EPS Diluted | -0.76 | -1.13 | -0.36 | -0.63 |
| Weighted Avg Shares Out | 318,635 | 277,984 | 271,453 | 271,720 |
| Weighted Avg Shares Out Dil | 318,635 | 277,984 | 271,453 | 271,720 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥328 | ¥327 | ¥327 | ¥328 |
| Depreciation & Amortization | ¥0 | ¥0 | ¥0 | ¥167,000 |
| EBITDA | -¥239,898 | -¥313,497 | -¥115,252 | -¥170,665 |
| % Margin | -104.1% | -155.6% | -61.7% | -50.5% |